Toxicology Cluster Chemotherapy Related Toxicity Drug Development Pipeline Review, 2017

NEW YORK, May 24, 2017 /PRNewswire/ -- Summary

This report provides an overview of the toxicology pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Chemotherapy Induced Nausea and Vomiting, Chemotherapy Induced Neutropenia, Chemotherapy Induced Anemia, Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects.

Chemotherapy induced nausea and vomiting or CINV is nausea and vomiting that results specifically from treatment with chemotherapy drugs. There are a total of 28 products in development for this indication, by 20 companies. Key companies operating in this pipeline space include Helsinn, Luxena Pharmaceuticals, Aphios, Nemus Bioscience and Tesaro.

Chemotherapy-induced neutropenia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness and abdominal pain. There are a total of 41 products in development for this indication, by 31 companies and one academic institution. Key companies operating in this pipeline space include Bolder Biotechnology, USV, Apotex, Biocon, Biogenomics, Generon and Pfizer.

Chemotherapy-induced anemia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness, cognitive impairment, loss of sexual desire, inability to perform daily functions and/or depression associated with anemia. There are a total of 16 products in development for this indication, by 14 companies. Key companies operating in this pipeline space include Chong Kun Dang and Tolero Pharmaceuticals.

Finally, chemotherapy-induced peripheral neuropathy (CIPN) is a further potential side effect of cancer treatment. Symptoms include pain, burning, tingling, constipation, muscle weakness, blood pressure changes and balance problems. There are a total of 41 products in development for this indication, by 34 companies and four academic institutions. Key companies operating in this pipeline space include Apexian Pharmaceuticals, Celgene and Metys Pharmaceuticals.

The dominant molecular targets vary across each of the four pipelines. In CINV and CIPN, there is a relatively diverse range of targets which are being studied. The 5-hydroxytryptamine receptor 3 and substance P receptors are most commonly being studied in CINV, as are the cannabinoid receptors 1 and 2. There is some overlap between this and the CIPN pipeline, with cannabinoid receptors being present amongst the relatively diverse range of targets in development, although with the glutamate ionotropic receptor NMDA-type being the most-frequently selected target.

In chemotherapy-induced neutropenia, on the other hand, the granulocyte colony stimulating factor receptor is overwhelmingly the target of choice, accounting for virtually the entire pipeline. Similarly, the erythropoietin receptor makes up the majority of the chemotherapy-induced anemia pipeline. This reflects the relatively focused nature of R&D within these two indications.

Scope

- Which companies are the most active within the pipeline for toxicology therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of toxicology therapeutics?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Read the full report: http://www.reportlinker.com/p04910726/Toxicology-Cluster-Chemotherapy-Related-Toxicity-Drug-Development-Pipeline-Review.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com


__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/toxicology-cluster-chemotherapy-related-toxicity-drug-development-pipeline-review-2017-300463340.html

SOURCE Reportlinker